Lucid Diagnostics closes $15 million financing through Series C Preferred Stock private placement, bolstering its balance sheet. The funding supports near-term commercial acceleration following the start of Medicare reimbursement for EsoGuard.
PUBLIC · LUCDOct 22, 2026
Amount Raised
$15 Million
Round Type
Series C
New YorkBiotechnology
Description
Lucid Diagnostics Inc. has begun receiving payments from Medicare for its EsoGuard® Esophageal DNA Test. The company closed a $15.0 million private placement for shares of its newly designated Series C Convertible Preferred Stock to existing long-term shareholders. This financing aims to strengthen Lucid's balance sheet and extend its cash runway
Who to call at Lucid Diagnostics, and when
A new round usually means Lucid Diagnostics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Lucid Diagnostics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Lucid Diagnostics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Lucid Diagnostics
Location
360 MADISON AVENUE
New York, New York, United States
About
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lucid Diagnostics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
New YorkBiotechnology